Background: Food allergies, particularly their severe and persistent forms, have a significant impact on children’s quality of life (QoL). Understanding and enhancing QoL is a crucial component of food allergy management. This study aimed to evaluate the QoL of Turkish children aged 0-12 years with IgE-mediated tree nut allergies (TNA) and explore influential factors, including parental anxiety. Methods: Primary caregiver-parents of children diagnosed with TNA completed the valid and reliable Food Allergy Quality of Life Questionnaire-Parent Form (FAQLQ-PF) and State-Trait Anxiety Inventory (STAI) to assess QoL and parental anxiety, respectively. Results: The study included 88 parents, predominantly mothers (83%). The children had a median age of 12 months (IQR 7.25-19.5). The mean FAQLQ-PF score was 3.55±1.34 without a statistical significance between age groups (0-3 years 3.15±1.28; 4-6 years 3.76±1.42; 7-12 years 3.73±1.19). Parents reported significantly worse FAQLQ-PF scores for children with hazelnut allergy, with a history of anaphylaxis, and who had to use an adrenaline autoinjector. State and trait anxiety scores were strongly correlated (r=0.584, p<0.001). There was significant but weak correlations between FAQLQ-PF and STAI domains. The multivariate linear regression analysis revealed that having a hazelnut allergy, a history of anaphylaxis, and higher parental state anxiety were all associated with poorer FAQLQ-PF scores, but, fathers tended to report better level of QoL. Conclusions: The QoL of Turkish children with TNA, as reported by parents, is influenced by various factors. Understanding and addressing these factors are crucial for a deeper understanding of how to enhance the accuracy of QoL assessment.

Background: Cystic fibrosis (CF) is reported to be a risk factor for drug hypersensitivity. However, there is conflicting data about true prevalence of drug allergy in children with CF. Methods: The suspicious drug hypersensitivity reactions (DHR) of children with CF were enquired by European Network for Drug Allergy (ENDA) questionnaire and skin tests and/or drug provocation tests were performed according to established guidelines. Results: Two hundred and nineteen children (48.9% boys; median [IQR] age, 8.4 years [4.8-12.4 years]) with cystic fibrosis were included in the study, from whom 22 patients with 24 suspected DHRs were evaluated. Most of the suspected DHRs were non-immediate (n=16, 66.6%) type and the offending drugs were amoxicillin clavulanic acid (n=7), macrolides (n=4), trimethoprim sulfamethoxazole (TMP/SMX) (n=2), piperacillin tazobactam (n=1), pancrelipase (n=1) and ursodeoxycholic acid (n=1). Eight (33.3%) of the DHRs were classified as immediate [ceftriaxone (n=2), ceftazidim (n=2), meropenem (n=1), ambisome (n=2), vancomycin (n=1)]. The main presenting clinical presentations were maculopapular eruption (41.6%) and urticaria (37.5%), accompanied by angioedema (8.3%), flushing (12.5%) and vomiting (8.3%). Nine skin tests (with beta-lactam protocol in 6 patients) and 24 DPTs were performed and none of the skin tests revealed a positive result, however 2 DPTs with TMP/SMX were positive. Conclusion: Actual drug allergy was demonstrated in 2 of 219 patients (0.9%) with nonbeta-lactam antibiotics. These results conflict with previous researches that showed higher drug allergy rates but were consistent with some recent studies. Numerous and long-term use of multiple drugs during management of cystic fibrosis may contribute to tolerance development.